Drug intelligence / Profile preview

azithromycin + artesunate

Development stage: Unknown
Lead developer: PLIVA
Modality: Small Molecules
Administration: Oral

Overview

Azithromycin + artesunate is a combination antimalarial treatment that pairs a macrolide antibiotic (azithromycin) with an artemisinin derivative (artesunate). This combination is used for the treatment of uncomplicated Plasmodium falciparum malaria. Azithromycin exerts slow but potent antimalarial activity via action against the apicoplast organelle, while artesunate provides rapid parasite clearance. The combination is particularly valuable because of azithromycin's safety profile in children and pregnant women, making it a potential alternative in areas with increasing antimalarial drug resistance.

Other names: azithromycin-artesunate combination

Targets

Plasmodium falciparum apicoplast 50S ribosomal subunit

Beyond the preview

Go deeper on azithromycin + artesunate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + artesunate.

Explore the full profile